(NASDAQ: APRE) Aprea Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.89%.
Aprea Therapeutics's earnings in 2025 is -$13,850,097.On average, 2 Wall Street analysts forecast APRE's earnings for 2025 to be -$4,834,967, with the lowest APRE earnings forecast at -$5,533,998, and the highest APRE earnings forecast at -$4,135,935. On average, 2 Wall Street analysts forecast APRE's earnings for 2026 to be -$4,106,809, with the lowest APRE earnings forecast at -$5,009,724, and the highest APRE earnings forecast at -$3,203,894.
In 2027, APRE is forecast to generate $1,922,336 in earnings, with the lowest earnings forecast at $1,922,336 and the highest earnings forecast at $1,922,336.